The Symphony of Survival: Sacubitril/Valsartan’s Heartfelt Impact on Mortality in Heart Failure: A Systemic Review

Abstract

Heart failure (HF) is a prevalent and debilitating condition affecting millions worldwide. Over the years, numerous therapeutic strategies have been employed to manage HF, improving patients' quality of life, and reducing morbidity and mortality rates.Sacubitril/valsartan, a novel combination drug, has emerged as a promising therapeutic option in the management of HF with reduced ejection fraction (HFrEF This abstract provides a comprehensive review of the use of sacubitril/valsartan in treating HF patients.It delves into the mechanism of action of both components, examining how sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin receptor blocker, work synergistically to address the complex pathophysiology of HFrEF. The unique combination of these agents has been shown to improve cardiac function, reduce ventricular remodeling, and mitigate neurohormonal activation, leading to better outcomes in HF patients. Several clinical trials and real-world studies have demonstrated the efficacy and safety of sacubitril/valsartan in HF management. These studies have highlighted the drug's ability to reduce HF-related hospitalizations and improve patients' functional status and exercise tolerance. Moreover, the combination therapy has shown a favorable risk-benefit profile, making it a valuable option for HF patients intolerant to angiotensin-converting enzyme (ACE) inhibitors.